Research Compound Database

Also: 5-Amino-1-methylquinolinium, NNMT Inhibitor

5-Amino-1MQ is a small molecule NNMT inhibitor that works by blocking the enzyme responsible for degrading NAD+ precursors in fat tissue. By inhibiting NNMT, it raises intracellular NAD+ levels, activates SIRT1 and downstream metabolic pathways, and shifts the metabolic phenotype of adipocytes — effectively reprogramming fat cells toward a leaner, more energy-consuming state.

Also: Acadesine, AICA Riboside, 5-Aminoimidazole-4-carboxamide ribonucleotide

AICAR is an AMP-activated protein kinase (AMPK) activator that mimics the metabolic effects of exercise at a cellular level, improving endurance, fat oxidation, glucose uptake, and metabolic efficiency without physical activity.

Also: Anti-Obesity Drug 9604, hGH Fragment 176-191

AOD-9604 is a modified fragment of human growth hormone specifically engineered to retain hGH's lipolytic (fat-burning) properties while eliminating its mitogenic and diabetogenic effects. It targets adipose tissue directly through a mechanism independent of IGF-1.

Also: AM833, Cagrilintide

Cagrilintide is a once-weekly amylin analog currently in pivotal Phase 3 trials as part of the CagriSema combination (with semaglutide). Acting on a complementary pathway to GLP-1, amylin analogs suppress glucagon, slow gastric emptying, and promote satiety through different brain circuits — providing additive weight loss when combined with GLP-1 agonists.

Also: LY3437943, Triple GIP/GLP-1/Glucagon Agonist

Retatrutide is a next-generation triple agonist peptide that simultaneously activates GIP (glucose-dependent insulinotropic polypeptide), GLP-1, and glucagon receptors. In Phase 2 trials it produced the largest weight loss ever seen in a pharmacological obesity trial — averaging 24% body weight reduction at 48 weeks.

Also: SLU PP 332, ERRα/γ agonist SLU-PP-332

SLU-PP-332 is a synthetic small-molecule agonist of estrogen-related receptors alpha and gamma (ERRα/ERRγ) — nuclear receptors that regulate mitochondrial biogenesis, oxidative metabolism, and energy expenditure. It mimics the metabolic effects of aerobic exercise at the cellular level, earning it the label of an 'exercise mimetic.' Studied for obesity, metabolic syndrome, heart failure, and muscular endurance.

Also: Ozempic, Wegovy, Rybelsus

Semaglutide is a GLP-1 receptor agonist peptide that has become one of the most significant metabolic therapeutics in recent history. Originally approved for type 2 diabetes, it has demonstrated unprecedented weight loss efficacy and is now being studied for cardiovascular protection, NASH, and Alzheimer's disease.

Also: Egrifta, TH9507

Tesamorelin is the only FDA-approved GHRH analog, indicated for HIV-associated lipodystrophy (excess abdominal fat accumulation). It stimulates GH release from the pituitary in a physiologically natural pulsatile manner and has demonstrated significant visceral fat reduction in clinical trials.

Also: Mounjaro, Zepbound, LY3298176, Dual GIP/GLP-1 Agonist

Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that has shown superior weight loss and glycemic control compared to semaglutide in head-to-head trials. It is the first drug in the 'twincretin' class and has become a cornerstone of modern obesity pharmacotherapy.